Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,348 | 308 | 98.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $125.00 | 1 | 1.5% |
| Education | $46.91 | 1 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,803 | 50 | $0 (2024) |
| ABBVIE INC. | $1,752 | 70 | $0 (2024) |
| GlaxoSmithKline, LLC. | $937.34 | 28 | $0 (2024) |
| Novo Nordisk Inc | $691.28 | 34 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $366.68 | 19 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $282.17 | 5 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $246.50 | 10 | $0 (2021) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $241.90 | 3 | $0 (2024) |
| ITI, Inc. | $235.96 | 3 | $0 (2023) |
| Lilly USA, LLC | $222.03 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,135 | 69 | AstraZeneca Pharmaceuticals LP ($507.18) |
| 2023 | $2,083 | 56 | ABBVIE INC. ($578.86) |
| 2022 | $607.76 | 19 | ABBVIE INC. ($196.06) |
| 2021 | $3,695 | 166 | AstraZeneca Pharmaceuticals LP ($726.00) |
All Payment Transactions
310 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $27.09 | General |
| Category: Obesity | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $94.96 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $9.15 | General |
| Category: Diabetes | ||||||
| 12/09/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: Endocrinology | ||||||
| 12/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: Cardio-renal | ||||||
| 11/27/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.91 | General |
| Category: Diabetes | ||||||
| 11/11/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $93.91 | General |
| Category: RESPIRATORY | ||||||
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: DIABETES | ||||||
| 10/21/2024 | Organon Llc | NEXPLANON (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: ETONOGESTREL | ||||||
| 10/14/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $34.23 | General |
| Category: Diabetes | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $115.92 | General |
| Category: Cardio-renal | ||||||
| 09/24/2024 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Food and Beverage | In-kind items and services | $8.76 | General |
| Category: VACCINES | ||||||
| 09/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: Diabetes | ||||||
| 09/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.20 | General |
| Category: DIABETES | ||||||
| 09/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $6.78 | General |
| Category: Diabetes | ||||||
| 09/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: Cardio-renal | ||||||
| 09/09/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: NEUROSCIENCE | ||||||
| 09/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $6.82 | General |
| Category: Diabetes | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.87 | General |
| 08/29/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/21/2024 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Food and Beverage | In-kind items and services | $7.97 | General |
| Category: VACCINES | ||||||
| 08/14/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $98.11 | General |
| Category: Psychology/Psychiatric | ||||||
| 08/14/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 346 | 677 | $73,596 | $38,006 |
| 2022 | 19 | 1,286 | 1,950 | $227,907 | $102,510 |
| 2021 | 18 | 605 | 936 | $106,128 | $51,328 |
| 2020 | 16 | 794 | 1,155 | $109,085 | $39,675 |
All Medicare Procedures & Services
65 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 110 | 275 | $38,771 | $21,201 | 54.7% |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | Office | 2023 | 18 | 135 | $6,750 | $4,642 | 68.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 54 | 73 | $7,180 | $3,710 | 51.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 26 | $5,063 | $2,610 | 51.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 36 | 36 | $8,458 | $2,080 | 24.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 14 | 14 | $1,854 | $1,564 | 84.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $3,284 | $1,070 | 32.6% |
| 87640 | Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | Office | 2023 | 15 | 15 | $750.00 | $515.85 | 68.8% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 25 | 40 | $388.40 | $380.80 | 98.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 14 | $524.56 | $125.92 | 24.0% |
| 81002 | Urinalysis, manual test | Office | 2023 | 15 | 20 | $69.60 | $68.20 | 98.0% |
| 81003 | Automated urinalysis test | Office | 2023 | 16 | 17 | $502.00 | $37.41 | 7.5% |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | Office | 2022 | 79 | 653 | $32,650 | $22,567 | 69.1% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2022 | 226 | 239 | $44,215 | $17,731 | 40.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 188 | 188 | $51,324 | $17,305 | 33.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 90 | 117 | $30,534 | $10,796 | 35.4% |
| 87631 | Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets | Office | 2022 | 51 | 51 | $11,818 | $7,056 | 59.7% |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | Office | 2022 | 225 | 238 | $10,710 | $5,886 | 55.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 53 | 55 | $10,207 | $4,115 | 40.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 27 | 30 | $8,488 | $3,724 | 43.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $12,093 | $3,547 | 29.3% |
| 87640 | Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | Office | 2022 | 69 | 70 | $3,500 | $2,394 | 68.4% |
| 87486 | Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique | Office | 2022 | 54 | 54 | $2,700 | $1,843 | 68.3% |
| 87581 | Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique | Office | 2022 | 53 | 53 | $2,650 | $1,806 | 68.1% |
| 87481 | Detection test for candida species (yeast), amplified probe technique | Office | 2022 | 31 | 32 | $1,600 | $1,080 | 67.5% |
About Tracy Candace Degenstein, ARNP
Tracy Candace Degenstein, ARNP is a Family healthcare provider based in Richland, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003895533.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Tracy Candace Degenstein, ARNP has received a total of $8,520 in payments from pharmaceutical and medical device companies, with $2,135 received in 2024. These payments were reported across 310 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($8,348).
As a Medicare-enrolled provider, Degenstein has provided services to 3,031 Medicare beneficiaries, totaling 4,718 services with total Medicare billing of $231,519. Data is available for 4 years (2020–2023), covering 65 distinct procedure/service records.
Practice Information
- Specialty Family
- Location Richland, WA
- Active Since 01/12/2006
- Last Updated 05/23/2024
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1003895533
Products in Payments
- FARXIGA (Drug) $953.22
- UBRELVY (Drug) $862.54
- CAPLYTA (Drug) $477.86
- BREZTRI (Drug) $464.38
- QULIPTA (Drug) $451.80
- TRELEGY ELLIPTA (Drug) $291.94
- Kerendia (Drug) $265.86
- SHINGRIX (Biological) $262.03
- NURTEC ODT (Drug) $251.17
- Austedo XR (Drug) $225.74
- AREXVY (Drug) $223.83
- Ozempic (Drug) $200.12
- INGREZZA (Drug) $196.73
- JARDIANCE (Drug) $189.87
- RYBELSUS (Drug) $150.24
- BEXSERO (Biological) $141.73
- CREON (Drug) $135.98
- FreeStyle Libre Pro (Device) $125.00
- AIRSUPRA (Drug) $122.29
- Auvelity (Drug) $118.03
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Richland
Christina Rodriguez, Arnp, ARNP
Family — Payments: $8,701
Robert Pleyo, Arnp, ARNP
Family — Payments: $4,660
Tina Highfill, Fnp-Bc, FNP-BC
Family — Payments: $4,404
Mr. Louie Ross, Fnp-Bc, FNP-BC
Family — Payments: $3,387
Diane Hanks, Arnp, ARNP
Family — Payments: $2,770
Mrs. Terri Davari, Arnp, ARNP
Family — Payments: $2,718